| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $152.00 $214.00 $728.00 $2601.00 $10965.00 $21838.00 $41096.00 | 5 | |
Suramin is known to interfere with the activity of various growth factors and enzymes. It may indirectly affect NDST1 by altering the cellular environment and influencing the metabolism of heparan sulfate. | ||||||
Tetraoctylammonium bromide | 14866-33-2 | sc-251208 sc-251208A sc-251208B sc-251208C | 5 g 25 g 100 g 250 g | $38.00 $121.00 $206.00 $428.00 | ||
Tetraoctylammonium bromide is a known inhibitor of sulfate activation and transport, processes crucial for heparan sulfate biosynthesis. By inhibiting these processes, chlorate can indirectly affect NDST1 function. | ||||||
Sodium chlorate | 7775-09-9 | sc-212938 | 100 g | $59.00 | 1 | |
Sodium Chlorate, similar to chlorate, inhibits sulfate activation and transport. It can have an indirect effect on NDST1 by disrupting the sulfate donor supply essential for NDST1's sulfotransferase activity. | ||||||
Foscarnet sodium | 63585-09-1 | sc-205330 sc-205330A | 1 g 5 g | $190.00 $676.00 | ||
Foscarnet sodium, a known inhibitor of various kinases and enzymes, could indirectly affect NDST1 by altering cellular signaling pathways related to heparan sulfate biosynthesis. | ||||||
Cyclophosphamide | 50-18-0 | sc-361165 sc-361165A sc-361165B sc-361165C | 50 mg 100 mg 500 mg 1 g | $90.00 $146.00 $469.00 $791.00 | 18 | |
Cyclophosphamide can indirectly influence NDST1 activity through its effects on cell growth and signaling pathways, potentially affecting heparan sulfate biosynthesis. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate, an antimetabolite, can indirectly affect NDST1 by influencing cellular metabolism and the biosynthesis of molecules, including glycosaminoglycans like heparan sulfate. | ||||||